Alam, MM; Solyakov, L; Bottrill, AR; Flueck, C; Siddiqui, FA; Singh, S; Mistry, S; Viskaduraki, M; Lee, K; Hopp, CS; Chitnis, CE; Doerig, C; Moon, RW; Green, JL; Holder, AA; Baker, DA; Tobin, AB (2015) Phosphoproteomics reveals malaria parasite Protein Kinase G as a signalling hub regulating egress and invasion. Nature communications, 6. p. 7285. ISSN 2041-1723 DOI: https://doi.org/10.1038/ncomms8285

Downloaded from: http://researchonline.lshtm.ac.uk/2235980/

DOI: 10.1038/ncomms8285

Usage Guidelines

Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alternatively contact researchonline@lshtm.ac.uk.

Available under license: http://creativecommons.org/licenses/by-nc-nd/2.5/
Supplementary Information

Phosphoproteomics reveals malaria parasite Protein Kinase G as a signalling hub regulating egress and invasion

Mahmood M. Alam1*, Lev Solyakov1*, Andrew R. Bottrill3, Christian Flueck2, Faiza Siddiqui4, Shailja Singh4, Sharad Mistry3, Maria Viskaduraki7, Kate Lee7, Christine S. Hopp2, Chetan E. Chitnis4, Christian Doerig5, Robert W. Moon6, Judith L. Green6, Anthony A. Holder6, David A. Baker2*, Andrew B. Tobin1*
Supplementary Figure 1

Phosphorylation of PfRAP1 – an example of the result of an OFF-target action of Compound 2
(A, B) Representative spectra from the global phosphoproteomic data demonstrating that the phosphorylation of serine-127 on PfRAP1 is down-regulated following Compound 2 treatment (2 µM, 60 minutes) of both wild type (A) and PKG_{T618Q} parasites (B). The inset on the left is a zoom of the spectrum to show the relative abundance of reporter ions from three experiments (126 and 127 from Expt. 1, 128 and 129 from Expt. 2, and 130 and 131 from Expt. 3). The inset on right hand side is the fragmentation table showing the observed b-ions (orange) and y-ions (blue). (C) Box plot display of the quantitative changes in abundance of a non-phosphorylated PfRAP1 peptide derived from wild type and PKG_{T618Q} mutant parasites and (D) of the phosphopeptide containing serine-127 of PfRAP1.
**Supplementary Figure 2**

**Effect of Compound 2 on the phosphorylation of PfCDPK1**

Parasites (schizont stage) expressing an HA-tagged PfCDPK1 were metabolically labelled with $^{32}$P orthophosphate and treated with vehicle or Compound 2 (2 µM, 40 minutes). The parasites were lysed and PfCDPK1 immunoprecipitated using anti-HA antibodies. Following separation by SDS-PAGE the samples were exposed to autoradiography. Coomassie blue staining of immunoprecipitated PfCDPK1 was used as a loading control. The results shown are representative of three independent experiments.
Supplementary Figure 3

Generation of a kinase dead mutant of *PfCDPK1*

An *in vitro* kinase reaction was carried out using bacterially expressed and purified HIS-tagged wild type *PfCDPK1* (1 µg) or a HIS-tagged ‘kinase dead’ mutant of *PfCDPK1* in which asparagine-191 was substituted by an aspartate (CDPK1-KD, 1µg), together with myelin basic protein (MBP, 2 µg) or histone (2 µg) as substrates. The reaction was stopped by addition of 2x Laemmli buffer and the proteins resolved by SDS PAGE on a 15% gel. The gel was stained with Coomassie blue, dried and exposed for autoradiography.
Supplementary Figure 4

Mass spectrometric determination of PfPKG mediated phosphorylation of PfCDPK1 at S64 and T231

Bacterially expressed and purified HIS-tagged CDPK1-KD (1 µg) was used in an in vitro kinase assay with recombinant PfPKG (1 µg). The reaction was then analysed by mass spectrometry to determine the sites of phosphorylation on CDPK1-KD. An example of a spectrum demonstrating phosphorylation of A. serine-64 and B. phosphorylation of threonine-231 is shown. C. The position of S64 and T231 within the primary amino acid sequence of PfCDPK1 is shown (the activation loop is in bold).
**Supplementary Figure 5**

**Catalytic activity and substrate specificity of PfCDPK1 is not dependent on serine-64 phosphorylation.**

**(A)** Recombinant, purified, HIS-tagged PfCDPK1 (1 µg) and mutant PfCDPK1 (1 µg) in which serine-64 was substituted by alanine (CDPK1-(S-A)) were assayed for protein kinase activity using MBP (2 µg), histone (2 µg) or α-casein (2 µg) as substrates. The proteins were resolved by SDS-PAGE on a 15% gel and an autoradiograph obtained. The results shown are typical of two experiments. **(B)** The kinase activity of HIS-tagged PfCDPK1 was assayed using MBP as a substrate in the presence or absence of recombinant PfPKG. Following different reaction times, aliquots of the reaction mix were transferred onto P81 nitrocellulose paper and counted for
radioactivity. The results are expressed as the mean of three experiments ± S.E.M. (C) Same as B except that the mutant CDPK1-(S-A) was used instead of wild type PfCDPK1. Student’s paired t-test was applied to test statistical significance ***p<0.001, **p<0.01, *p<0.05.

Supplementary Figure 6

_PfPKG is not part of the high molecular weight PfCDPK1 complex but exists as monomer._

Parasite lysate (300 µl, approx. 1mg total protein) was fractionated over a Superdex 200 gel filtration column and the fractions probed by Western blot with an anti-PfPKG antibody. A 15 µl aliquot of lysate was run as a pre-column loading control (lysate). Shown is a representative of three independent experiments.
Supplementary Figure 7

Generation of PfCDPK1-HA parasites

(A) Scheme for generating HA-tagged CDPK1 parasites by single crossover recombination. (B) Diagnostic PCR to confirm integration of the plasmid at the pfcdpk1 locus. Primers 4 and 5 give a product only when correct integration of the plasmid has taken place (lane a), and primers 4 and 6 give a product only from the uninterrupted locus (lane b). For primer sequences see; Primers in supplementary methods.
Supplementary Figure 8

Distribution of the changes in the abundance of peptides identified in each of the three global mass spectrometry studies conducted on the wild type *P. falciparum* parasite cultures.

Wild type parasites were treated with vehicle or Compound 2 (2 µM, 60 mins), lysed, trypically digested and the peptides labelled with isobaric tags before the phospho-peptides were enriched. The peptides were then analysed by mass spectrometry and the distribution curves representing changes in the abundance of the peptides plotted. Those phospho-peptides that were seen to be present in the lower quartile of the distribution curves in all three experiments were then compared with the same peptides present in the three global phosphoproteomic experiments conducted on the PKG_{T618Q} mutant parasites. Those phosphopeptides that were seen to be reduced in both the wild type and mutant parasites were considered to represent the off-target action of Compound 2 and those peptides that were only seen to be reduced in the wild type parasites were the on-target action of Compound 2 and therefore considered as cellular targets for *PfPKG*. 
Supplementary Table 4

<table>
<thead>
<tr>
<th>PRIMER</th>
<th>SEQUENCE</th>
</tr>
</thead>
<tbody>
<tr>
<td>CDPK1_FL_His_Fwd</td>
<td>AGGAGATATACATATGGGGGTGTTGTCACAAAAGGTCAACG</td>
</tr>
<tr>
<td>CDPK1_FL_His_Rev</td>
<td>GAAGTACAGTTCTGATTGATTTATTTATTATGCCAAAATTATTGTGACATCG</td>
</tr>
<tr>
<td>CDPK1_FL_GST_Fwd</td>
<td>ATCGGGATCCATGGGTGTTGTCACAAAAGGTCAACG</td>
</tr>
<tr>
<td>CDPK1_FL_GST_Rev</td>
<td>ATCGGGATCCCTTATGAAGATTTATTTATCACAAAATTATTGTGACATCG</td>
</tr>
<tr>
<td>CDPK1_D191N_Fwd</td>
<td>CATATTTATTTTACATCAATATGTTGTACATCGAAAAATATTTATTAGAAAAATAAACA</td>
</tr>
<tr>
<td>CDPK1_D191N_Rev</td>
<td>TGGTTATTTTCTAATAATAATATTTTCTGTTTTAAATATTATTTGACATCG</td>
</tr>
<tr>
<td>CDPK1_S64A_Fwd</td>
<td>CTATTCAGAATTCTCGACAATTTACTGCGGTGTTGACATCG</td>
</tr>
<tr>
<td>CDPK1_S64A_Rev</td>
<td>TCGTACCGCAACCGACCTAATATTTGACATCG</td>
</tr>
<tr>
<td>PRIMER 1</td>
<td>ACACCCGGGTTATACAAACTGAAAAATATTTTTTTC</td>
</tr>
<tr>
<td>PRIMER 2</td>
<td>ATATGGGTCAGCCTTTCATTTTTCTTTTC</td>
</tr>
<tr>
<td>PRIMER 5</td>
<td>CCCAATCTGTCCTATGCTTTTTTTC</td>
</tr>
<tr>
<td>PRIMER 6</td>
<td>CTGTTTAAATATCTCGATGTTATATTGTGTTATG</td>
</tr>
</tbody>
</table>

Supplementary Table 1

List of PCR primers used in this study.